Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Entourage Health Corp V.ENTG

Alternate Symbol(s):  ETRGF

Entourage Health Corp. is a Canada-based license holder producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a 26,000 square feet indoor facility in Aylmer, Ontario (the Aylmer Facility), specializing in product development and fulfillment for both adult-use and medical cannabis. The Company is focused on building a portfolio of brands in the Canadian market, including its brand Color Cannabis, mainstream brand Saturday Cannabis, medical cannabis product brand Starseed Medicinal and its craft cannabis brand Syndicate Cannabis. The Company produces a diverse portfolio of cannabis and cannabis derivative products, including oils, capsules, soft chews, topicals, beverages and vapes, for sale in both the medical and adult-use markets across Canada. Its elite adult-use product portfolio also includes Dime Bag a pre-roll offering, sold across eight provincial distribution agencies.


TSXV:ENTG - Post by User

Bullboard Posts
Comment by DSeng89on Jun 11, 2019 9:58am
117 Views
Post# 29814910

RE:RE:Bioassets, EPS and market cap come Q3 2019

RE:RE:Bioassets, EPS and market cap come Q3 2019Agreed Walter. Come Q3/Q4, these guys will begin to stand out against other small caps. Their revenues will continue to rise for the foreseeable future and as long as they can continue to manage their cash efficiently, I can't see us sitting at these levels by year end. The summer lull coupled with no news until End-July has resulted in a lack of volume and traders investing elsewhere. 

]
Walterthedog wrote: I agree there is a ticking time bomb there as investors will catch wind of a major increase like that quickly. Thats why i was surprised we didn't rise more with the news about getting the license. However if you think that they will get their upper end estimates of 27 000 kgs and then be able to sell it for 6$/gram or even the eventual equivalent in oil sales you must be pretty high. Even if you can get a little better margins on oil, theres no way they will post such an increase based on an outdoor crop that would face an increased amount of uncertainty. You also have to take out costs to produce. I'm guessing they post an increase of 30 to 50M$. Thats still awesome when tacked on to your eps for the quarter and i fully believe it'll get more eyes on WMD.


Bullboard Posts